NO2310396T3 - - Google Patents

Info

Publication number
NO2310396T3
NO2310396T3 NO09793887A NO09793887A NO2310396T3 NO 2310396 T3 NO2310396 T3 NO 2310396T3 NO 09793887 A NO09793887 A NO 09793887A NO 09793887 A NO09793887 A NO 09793887A NO 2310396 T3 NO2310396 T3 NO 2310396T3
Authority
NO
Norway
Application number
NO09793887A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2310396T3 publication Critical patent/NO2310396T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO09793887A 2008-07-08 2009-07-08 NO2310396T3 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04
PCT/EP2009/004942 WO2010003658A1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
EP09793887.2A EP2310396B1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
NO2310396T3 true NO2310396T3 (zh) 2018-02-03

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09793887A NO2310396T3 (zh) 2008-07-08 2009-07-08

Country Status (32)

Country Link
US (2) US8921355B2 (zh)
EP (1) EP2310396B1 (zh)
JP (2) JP5426671B2 (zh)
KR (1) KR101640374B1 (zh)
CN (1) CN102089314B (zh)
AP (1) AP2743A (zh)
AR (1) AR072726A1 (zh)
AU (1) AU2009267389B8 (zh)
BR (1) BRPI0915887B8 (zh)
CA (1) CA2729307C (zh)
CL (1) CL2011000032A1 (zh)
CO (1) CO6351793A2 (zh)
CR (1) CR20110076A (zh)
DK (1) DK2310396T3 (zh)
EA (1) EA019008B1 (zh)
EC (1) ECSP11010750A (zh)
ES (1) ES2651038T3 (zh)
HK (1) HK1155734A1 (zh)
HN (1) HN2011000072A (zh)
HR (1) HRP20171892T1 (zh)
HU (1) HUE035244T2 (zh)
IL (1) IL210086A (zh)
LT (1) LT2310396T (zh)
MX (1) MX2011000276A (zh)
NI (1) NI201100010A (zh)
NO (1) NO2310396T3 (zh)
NZ (2) NZ603343A (zh)
SI (1) SI2310396T1 (zh)
SV (1) SV2011003796A (zh)
TW (1) TWI454476B (zh)
UY (1) UY31973A (zh)
WO (1) WO2010003658A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2389994T3 (es) 2007-12-24 2012-11-05 Janssen R&D Ireland Indoles macrocíclicos como inhibidores del virus de la hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
KR20130057990A (ko) * 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 마크로사이클릭 ｈｃｖ 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물
JP5870098B2 (ja) * 2010-06-24 2016-02-24 ヤンセン・サイエンシズ・アイルランド・ユーシー １３−シクロヘキシル−３−メトキシ−６−［メチル−（２−｛２−［メチル−（スルファモイル）−アミノ］−エトキシ｝−エチル）−カルバモイル］−７Ｈ−インドロ−［２，１−ａ］−［２］−ベンズアゼピン−１０−カルボン酸の製造
WO2013030803A1 (en) 2011-09-02 2013-03-07 Novartis Ag Choline salt of an anti - inflammatory substituted cyclobutenedione compound
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
AU2013311025A1 (en) 2012-08-31 2015-02-26 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
WO2019133574A2 (en) * 2017-12-26 2019-07-04 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
ES2405316T3 (es) 1999-03-19 2013-05-30 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima IMPDH
CN1290140C (zh) 2000-08-30 2006-12-13 松下电器产业株式会社 等离子体显示装置及其制造方法
NZ548740A (en) 2004-01-30 2010-06-25 Medivir Ab HCV NS-3 Serine protease inhibitors
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2009507004A (ja) 2005-09-02 2009-02-19 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｃｖ阻害剤としてのベンゾジアゼピン
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
US8101595B2 (en) * 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
AU2008277440A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
AU2010219160B2 (en) 2009-02-27 2015-12-10 Ortho-Mcneil-Janssen Pharmaceuticals Inc Amorphous salt of a macrocyclic inhibitor of HCV
KR20130057990A (ko) 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 마크로사이클릭 ｈｃｖ 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물
JP5870098B2 (ja) 2010-06-24 2016-02-24 ヤンセン・サイエンシズ・アイルランド・ユーシー １３−シクロヘキシル−３−メトキシ−６−［メチル−（２−｛２−［メチル−（スルファモイル）−アミノ］−エトキシ｝−エチル）−カルバモイル］−７Ｈ−インドロ−［２，１−ａ］−［２］−ベンズアゼピン−１０−カルボン酸の製造
AU2013311025A1 (en) 2012-08-31 2015-02-26 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir

Also Published As

Publication number Publication date
AU2009267389A8 (en) 2013-07-04
JP2011527299A (ja) 2011-10-27
WO2010003658A1 (en) 2010-01-14
KR101640374B1 (ko) 2016-07-18
AU2009267389B8 (en) 2013-07-04
US8921355B2 (en) 2014-12-30
HRP20171892T1 (hr) 2018-01-12
DK2310396T3 (en) 2017-12-11
US20140107101A1 (en) 2014-04-17
EA019008B1 (ru) 2013-12-30
EP2310396B1 (en) 2017-09-06
AP2743A (en) 2013-09-30
CL2011000032A1 (es) 2011-07-15
MX2011000276A (es) 2011-03-02
EA201170153A1 (ru) 2011-08-30
CN102089314B (zh) 2014-07-23
BRPI0915887B1 (pt) 2020-02-18
JP2014028818A (ja) 2014-02-13
JP5808370B2 (ja) 2015-11-10
ECSP11010750A (es) 2011-08-31
US9427440B2 (en) 2016-08-30
KR20110040889A (ko) 2011-04-20
CR20110076A (es) 2011-11-10
HK1155734A1 (zh) 2012-05-25
CN102089314A (zh) 2011-06-08
CO6351793A2 (es) 2011-12-20
SI2310396T1 (en) 2018-01-31
NZ590073A (en) 2012-11-30
AP2010005521A0 (en) 2010-12-31
SV2011003796A (es) 2011-04-08
UY31973A (es) 2010-01-29
IL210086A (en) 2014-05-28
CA2729307A1 (en) 2010-01-14
HUE035244T2 (hu) 2018-05-02
HN2011000072A (es) 2013-09-01
AU2009267389B2 (en) 2013-05-30
IL210086A0 (en) 2011-02-28
NZ603343A (en) 2013-08-30
AU2009267389A1 (en) 2010-01-14
NI201100010A (es) 2011-09-07
BRPI0915887A2 (pt) 2015-11-03
CA2729307C (en) 2017-08-29
LT2310396T (lt) 2017-12-27
EP2310396A1 (en) 2011-04-20
BRPI0915887B8 (pt) 2021-05-25
AR072726A1 (es) 2010-09-15
TWI454476B (zh) 2014-10-01
US20110105473A1 (en) 2011-05-05
ES2651038T3 (es) 2018-01-23
TW201014865A (en) 2010-04-16
JP5426671B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
BR112016019572A2 (zh)
BRPI0909040A2 (zh)
BRPI0917573A2 (zh)
BRPI0908549B8 (zh)
BRPI0918697A2 (zh)
BRPI0917525A2 (zh)
BRPI0920750A2 (zh)
BRPI0919470A2 (zh)
BRPI0922455A2 (zh)
BRPI0907698A2 (zh)
BRPI0917618A8 (zh)
BRPI0912727A2 (zh)
BRPI0908285A2 (zh)
BRPI0910485A2 (zh)
BRPI0922669A2 (zh)
BRPI0914750A2 (zh)
BRPI0908120A2 (zh)
BRPI0904541A8 (zh)
BRPI0912462A2 (zh)
BRPI0915616A2 (zh)
BRPI0919811A2 (zh)
BRPI0920914A2 (zh)
BRPI0916284A2 (zh)
BRPI0922550A2 (zh)
BRPI0911617A2 (zh)